Business
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILADELPHIA, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM:
About this update from Avacta Group Plc
[{"type":"image","alt":"AVACTA GROUP PLC","displaySize":"","headline":null,"caption":"AVACTA GROUP PLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BuJbdPFE1KPW3OqbkUSHWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2179b51c1f91cddf1addee3cc0dee04b","width":300,"height":109}},"lazy":false},{"type":"text","content":"Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91%","length":218,"tagName":"p"},{"type":"text","content":"No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m²","length":195,"tagName":"p"},{"type":"text","content":"LONDON and PHILADELPHIA, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION®, a unique oncology delivery platform, today announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin (FAP-Dox, AVA6000) to be presented at the 2025 European Society of Medical Oncology Annual Congress in Berlin, Germany.","length":454,"tagName":"p"},{"type":"text","content":"Faridoxorubicin treatment data demonstrate favorable safety and tolerability across both the every three weeks and every two weeks dosing regimens. The trial data also demonstrate a robust reduction in toxicities associated with conventional doxorubicin therapy, with preliminary efficacy in patients with salivary gland cancers and soft tissue sarcomas. Cardiac safety data in patients treated above the standard cumulative dose demonstrate no severe toxicity observed either in treatment stage or in follow up and no severe cardiac adverse events were reported in the trial, regardless of the cumulative dose level.","length":617,"tagName":"p"},{"type":"text","content":"Median progression-free survival (PFS) has not been reached in the previously-reported cohort of patients with salivary gland cancers, ind...